Business Wire

Halfords Delivers Consistent and Convenient Shopping Experiences with Juniper Networks’ AI-driven Wired and Wireless Access Solutions

19.4.2023 11:00:00 EEST | Business Wire | Press release

Share

Juniper Networks ®, (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Halfords, the UK’s leading provider of motoring and cycling products and services selected Juniper’s AI-driven wired and wireless access solutions in its stores, garages and offices to serve as a flexible foundation for its business growth and operational efficiency. The 125-year-old company has invested heavily to accelerate its digital transformation, leveraging the benefits of Mist AI and the cloud to create better commercial services and a unified, omnichannel retail experience for its customers. Halfords has reduced network-related trouble tickets by 100 percent and has seen a 35 percent improvement in uptime in the garages and stores where the deployment has been completed.

The Juniper® AI-driven network provides an agile digital foundation for Halfords’ continued success and drives a more consistent and convenient customer experience across locations and channels. It can tailor communications to Halfords Motoring Club members when they come to the store. The new network provides employees details about products such as child seats, cycle racks and roof racks, so they can have informed conversations with customers and sell with greater confidence.

Halfords pivoted during the pandemic, with strong growth in online sales and the addition of contactless tactics such as click-and-collect in its parking lots. Its innovative mobile field service software was key to delivering 70,000 services safely and efficiently per week for more than four years at its auto centers and customers’ homes. Many pandemic-motivated shopping behaviors are now permanent, requiring an IT infrastructure that is flexible and scalable enough to support changing customer demands.

As shoppers return to stores to test drive an electric bike, get an oil change or replace worn tires, for example, reliable wired and wireless connectivity is essential for both workers and shoppers alike. Halfords had an aging in-store network that was increasingly a roadblock to sales and service due to inconsistent performance and difficult troubleshooting, which resulted in poor user and operator experiences. To address this, the retailer is now deploying a Juniper wired and wireless network across its retail stores, auto centers and offices. Mist AI works in conjunction with Juniper Access Points to deliver scalable and reliable Wi-Fi 6 and virtual Bluetooth® LE services to Halfords’ staff and customer smartphones, point-of-sale devices, in-store video displays and other connected devices. Juniper EX Series switches provide high-performance, secure access to wired devices with AI-driven automation and insights for easy provisioning, troubleshooting and operations. Marvis™, the industry’s only virtual network assistant driven by Mist AI, provides proactive actions for easy fault identification and self-driving network operations for fast and proactive correction. Juniper is a Leader in the 2022 Gartner® Magic Quadrant™ for Enterprise Wired and Wireless LAN Infrastructure for the 3rd year in a row, positioned highest on the ability to execute axis and furthest to the right on the completeness of vision axis.

Halfords plan to transform its network further with the modernization of its WAN, which connects its 1400+ stores, auto centers and mobile service vans. To achieve this, they are also planning to deploy Juniper’s AI-driven SD-WAN solution, which leverages the same cloud and Mist AI engine as their new wired and wireless network. By deploying a full-stack Juniper solution, Halfords can achieve superlative insight into end-to-end user experiences and the superior automation from client-to-cloud.

Halfords worked with ConnectedID, a Juniper partner, to create the optimal network architecture, working on the design, validation and testing to ensure that the Juniper solutions met Halfords’ strategic goals.

Supporting Quotes:

“The network is a utility. It is a big part of our digital transformation journey, and we needed a very intelligent, secure network with next-generation capabilities. Juniper is a disruptor in the industry. The network user experience that it offers far exceeds anything else in the market. The ease of operations and self-healing capabilities of Juniper’s technology, along with the user experience metrics it delivers for Halfords, are outstanding.”

- Neil Holden, Chief Information Officer, Halfords

“Smart retailers like Halfords are leveraging AI technologies to ensure customers’ shopping experiences are positive at every touchpoint. Halfords has invested in Juniper’s AI solutions to build a more detailed picture of its customers to keep up with changing consumer behavior. Mist AI helps Halfords optimize user experiences and simplify IT operations with automated network assurance and the proactive problem detection and resolution. Users and devices have predictable connectivity and the number of network-related trouble tickets have dropped by 100 percent.”

- Gos Hein van de Wouw, Vice President, Enterprise, EMEA, Juniper Networks

Additional Resources:

About Juniper Networks

Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

Category – AI

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Pelin Murphy
Juniper Networks
+44 (0) 1372 385 686
pelin@juniper.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye